The “Gordian Knot” is a legendary tale of an unbreakable intricate knot, which could never be unraveled until Alexander the Great boldly cut the knot with his sword, fulfilling the legend that he would become the next ruler of Asia. Since then, the Gordian Knot has become a metaphor for impossible to solve medical, political, and mathematical problems. The logo of PridCor Therapeutics, LLC illustrates our commitment to unraveling the “Gordian Knot” that is Long COVID and other instances of post viral syndrome.
Pharmaceutical companies and academic research centers struggle with expensive, time consuming, non-productive, single-agent clinical trials for chronic ailments like fibromyalgia, MECFS, and now Long COVID. They have been unable to unravel the complexities of these post viral illnesses.
PridCor is developing an investigational combination regimen designed to address proposed biological drivers of Long COVID. If the approach is validated in controlled studies, it may also be relevant to related conditions including ME/CFS, fibromyalgia, and IBS.
SARS CoV-2 triggered the worst pandemic in over 100 years. Tragically, for many, this illness produced a post viral syndrome that resulted in dramatic systemic and immune alterations. An estimated 400 million people worldwide have been affected by Long COVID on a cumulative basis (Al-Aly Z, et al. Nature Medicine. 2024;30(8):2148-2164).
The societal and financial consequences of Long COVID will be enormous with an estimated annual global economic impact of approximately $1 trillion (same source). Congress appropriated $1.15 billion to the National Institutes of Health in December 2020 to study the long-term effects of COVID-19, with a further $662 million in 2024.
PridCor Therapeutics, LLC is collaborating with researchers at the Icahn School of Medicine at Mount Sinai on the SHIELD Study, a randomized, quadruple-masked, placebo-controlled Phase 2 study registered as NCT07597902, designed to evaluate the safety and efficacy of the regimen in approximately 150 adults with Long COVID.
It is widely known that traditionally, medical researchers like their progress to come in small incremental changes. Said more concisely, science advances one “funeral at a time.” PridCor Therapeutics, LLC sees the “Gordian Knot” as not merely a legend, but an urgent call needed for change. It is a bold new philosophy and guiding principle for future biotech companies to strive for leaping groundbreaking discoveries.
Bringing over three decades of experience in venture capital, strategic leadership, and biotechnology innovation. Known for his ability to identify and cultivate transformative healthcare technologies, Brian has successfully guided numerous biotech ventures from early-stage development through commercialization, leveraging his extensive network within the venture capital community.
As the Chairman and CEO of BullBear Partners, a private investment firm he founded in 2002, Brian has consistently championed investments in groundbreaking biotech and medical device enterprises. His strategic foresight and deep understanding of capital markets have driven significant growth and value creation for his portfolio companies, positioning them as industry leaders.
Prior to establishing BullBear Partners, Brian held executive roles at Drop “premier” and keep the three firms only if dates and titles are on file, where he specialized in mergers, acquisitions, capital trading, and funding strategies. His distinguished career is marked by his commitment to building companies founded on integrity, innovation, and sustainable value.
At PridCor Therapeutics, Brian leads PridCor’s corporate strategy and operations.
Brian is an alumnus of the University of Georgia and remains actively involved in international affairs, charitable endeavors, and community coaching initiatives, reflecting his dedication to positive impact beyond the business sphere.
Co-Founder & Chief Executive Officer
Successfully Founded Virios Therapeutics now trading as Dogwood Therapeutics on the NASDAQ.
With over two decades of clinical expertise as a board-certified surgeon, Dr. Pridgen developed the PridCor Protocol, an investigational regimen designed to address proposed biological drivers of Long COVID.
Driven by an unwavering commitment to patient care and scientific innovation, Dr. Pridgen uniquely combines extensive real-world clinical experience with pioneering research. His innovative approach has significantly advanced the understanding of chronic viral conditions and has positioned PridCor Therapeutics at the forefront of healthcare innovation.
Dr. Pridgen’s visionary leadership and deep understanding of both clinical practice and pharmaceutical development.
